Welcome to our dedicated page for First Wave BioPharma news (Ticker: FWBI), a resource for investors and traders seeking the latest updates and insights on First Wave BioPharma stock.
First Wave BioPharma, Inc. (FWBI) is a leading biopharmaceutical company dedicated to developing non-systemic, recombinant protein therapies targeting gastrointestinal diseases and related conditions. Headquartered in New York, NY, with scientific operations based in Langlade, France, First Wave BioPharma aims to be at the forefront of innovative treatments in the biotech industry.
The company's flagship development program is MS1819 recombinant lipase, which is in advanced stages of development for treating exocrine pancreatic insufficiency (EPI). This condition often affects patients with cystic fibrosis and chronic pancreatitis, and MS1819 offers a promising alternative to current enzyme replacement therapies.
Besides MS1819, First Wave BioPharma is working diligently on early-stage research projects aimed at preventing hospital-acquired infections, further solidifying its focus on significant unmet medical needs.
In 2024, First Wave BioPharma plans to advance its gastrointestinal (GI) development pipeline significantly. The company expects to add the Phase 3 Latiglutenase celiac disease program and multiple Phase 2 clinical programs featuring Capeserod and Adrulipase. These initiatives are contingent upon the potential merger with ImmunogenX, a deal that could mark a year of substantial growth for the company.
Recent news highlights multiple clinical and development milestones anticipated in 2024, including the initiation of a Phase 3 clinical trial investigating latiglutenase in celiac disease. This trial is pivotal for the company's future, given the significant growth potential it represents in treating celiac disease effectively.
For detailed information and the latest updates, reach out to First Wave BioPharma at their Boca Raton office or through their media contact at Tiberend Strategic Advisors, Inc.
Entero Therapeutics, formerly First Wave BioPharma, has rebranded to reflect its focus on gastrointestinal (GI) diseases. The company, now trading under the ticker 'ENTO' effective May 17, 2024, is advancing toward a Phase 3 trial for latiglutenase. This lead asset has shown promise in Phase 2 trials for treating celiac disease, a condition with no current approved treatments. The rebranding follows the acquisition of ImmunogenX and aims to align with Entero's mission to address unmet needs in GI health. The Phase 3 trial is expected to commence in early 2025. Entero will also participate in Celiac Awareness Month by partnering with Celiac Journey for a digital display at the Nasdaq Tower in Times Square.
First Wave BioPharma, Inc. is set to raise approximately $1.1 million in gross proceeds through a registered direct offering priced at-the-market. The Company entered into a securities purchase agreement with an institutional investor for the sale of 366,000 shares of common stock at $2.95 per share. Additionally, warrants to purchase up to 732,000 shares will be issued to the investor at $2.70 per share. The offering, facilitated by Roth Capital Partners, aims to bolster the Company's working capital and general corporate purposes.
First Wave BioPharma, Inc. (NASDAQ: FWBI) partners with Celiac Journey for Celiac Disease Awareness Month to host an event at Nasdaq Tower in Times Square. The event aims to raise awareness about celiac disease, advocate for research, and support the 3.3 million individuals in the U.S. impacted by the condition. The company will showcase a digital display and host a photo event featuring celiac disease advocates and experts. CEO James Sapirstein highlights the lack of treatment options for celiac disease and the company's dedication to developing innovative therapies for GI diseases. Co-founder of Celiac Journey, Jax Bari, emphasizes the challenges faced by individuals with celiac disease and the need for improved research funding and alternative treatments. Co-founder Jon Bari stresses the importance of labeling gluten grains for a better quality of life and safety for celiacs.
FAQ
What is the current stock price of First Wave BioPharma (FWBI)?
What is the market cap of First Wave BioPharma (FWBI)?
What is First Wave BioPharma, Inc.'s core business?
What is MS1819 recombinant lipase?
Where is First Wave BioPharma headquartered?
What are the significant upcoming milestones for First Wave BioPharma in 2024?
How can I contact First Wave BioPharma for more information?
What potential growth opportunities are there for First Wave BioPharma?
What research is First Wave BioPharma conducting besides MS1819?
What is the significance of the Phase 3 latiglutenase program?
How has First Wave BioPharma performed in recent advancements?
What impact does the merger with ImmunogenX have on First Wave BioPharma?
